Cancer immunotherapy can induce sustained responses in patients with cancers in a broad
range of tissues, however, these treatments require the optimized combined therapeutic …

Therapeutic cancer vaccines have proven to seldom induce dramatic clinical response
when used alone, and therefore, they are being studied in combination with additional …

Cancer vaccines and immune checkpoint inhibitors (ICIs) function at different stages of the
cancer immune cycle due to their distinct mechanisms of action. Therapeutic cancer …

Therapeutic cancer vaccines have become increasingly qualified for use in personalized
cancer immunotherapy. A deeper understanding of tumor immunology and novel antigen …

Therapeutic cancer vaccines have gained significant popularity in recent years as new
approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines …

Tumor vaccines have been an attractive concept in the immunotherapy of cancer based on
the central role of tumor-associated antigens in allowing the immune system to recognize …

Dramatic success in cancer immunotherapy has been achieved over the last decade with
the introduction of checkpoint inhibitors, leading to response rates higher than with …

Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic
development for cancer treatment. However, many cancer patients do not respond to …

Clinical approval of the immune checkpoint blockade (ICB) agents for multiple cancer types
has reinvigorated the long-standing work on cancer vaccines. In the pre-ICB era, clinical …

This comprehensive review delves into the rapidly evolving arena of cancer vaccines.
Initially, we examine the intricate constitution of the tumor microenvironment (TME), a …